PKO Investment Management Joint Stock Co Boosts Holdings in IQVIA Holdings Inc. $IQV

PKO Investment Management Joint Stock Co raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 14.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,000 shares of the medical research company’s stock after purchasing an additional 1,000 shares during the quarter. PKO Investment Management Joint Stock Co’s holdings in IQVIA were worth $1,261,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in IQV. Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after purchasing an additional 131 shares during the period. Golden State Wealth Management LLC grew its stake in shares of IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 130 shares during the last quarter. AllSquare Wealth Management LLC acquired a new position in IQVIA during the first quarter worth $33,000. Trust Co. of Toledo NA OH acquired a new position in IQVIA in the second quarter valued at $39,000. Finally, J.Safra Asset Management Corp boosted its position in shares of IQVIA by 208.6% in the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after buying an additional 169 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IQV has been the topic of several research analyst reports. Evercore ISI raised their price target on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research report on Wednesday, October 8th. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Redburn Partners set a $214.00 target price on shares of IQVIA in a research report on Wednesday, September 3rd. Cowen reissued a “buy” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Finally, Hsbc Global Res raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $234.57.

IQVIA Stock Performance

IQVIA stock opened at $220.64 on Friday. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $225.91. The firm has a market capitalization of $37.51 billion, a PE ratio of 31.93, a price-to-earnings-growth ratio of 2.42 and a beta of 1.32. The firm’s 50 day simple moving average is $194.47 and its 200 day simple moving average is $171.27. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion during the quarter, compared to analysts’ expectations of $3.96 billion. During the same quarter in the prior year, the company posted $2.64 EPS. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.